126 related articles for article (PubMed ID: 1826095)
1. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
[TBL] [Abstract][Full Text] [Related]
2. [Long-term hemodialysis and changes in variables of coagulation and fibrinolysis].
Uchida Y
Fukuoka Igaku Zasshi; 1991 Nov; 82(11):576-85. PubMed ID: 1774013
[TBL] [Abstract][Full Text] [Related]
3. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222.
Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR
Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924
[TBL] [Abstract][Full Text] [Related]
5. Indices of fibrinogen proteolysis and platelet activation during the resolution of pulmonary embolism.
Yudelman I
Thromb Haemost; 1987 Feb; 57(1):11-6. PubMed ID: 2954258
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.
Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR
Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403
[TBL] [Abstract][Full Text] [Related]
7. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
[TBL] [Abstract][Full Text] [Related]
8. Coagulation responses to heparin in the ischemic limb: assessment of thrombin and platelet activation during vascular surgery.
Sobel M; Gervin CA; Qureshi DG; Greenfield LJ
Circulation; 1987 Sep; 76(3 Pt 2):III8-13. PubMed ID: 2957118
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of platelets and plasma proteolytic systems during the early stages of Rocky Mountain spotted fever.
Rao AK; Schapira M; Clements ML; Niewiarowski S; Budzynski AZ; Schmaier AH; Harpel PC; Blackwelder WC; Scherrer JR; Sobel E
N Engl J Med; 1988 Apr; 318(16):1021-8. PubMed ID: 2965302
[TBL] [Abstract][Full Text] [Related]
10. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin.
Gallino A; Haeberli A; Hess T; Mombelli G; Straub PW
Am Heart J; 1986 Aug; 112(2):285-90. PubMed ID: 2426934
[TBL] [Abstract][Full Text] [Related]
11. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis.
Ryan KE; Lane DA; Flynn A; Shepperd J; Ireland HA; Curtis JR
Thromb Haemost; 1991 Sep; 66(3):277-82. PubMed ID: 1745997
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes.
Kario K; Matsuo T; Kodama K; Matsuo M
Thromb Res; 1992 Jun; 66(5):509-15. PubMed ID: 1523607
[TBL] [Abstract][Full Text] [Related]
13. Dialysis membranes and coagulation system.
Notohamiprodjo M; Andrassy K; Bommer J; Ritz E
Blood Purif; 1986; 4(1-3):130-41. PubMed ID: 2942155
[TBL] [Abstract][Full Text] [Related]
14. Hemodialysis with defibrotide: effects on coagulation parameters.
Filimberti E; Cinotti S; Salvadori M; Amato M; Longo G; Nazzari M; Morfini M
Int J Artif Organs; 1992 Oct; 15(10):590-4. PubMed ID: 1428206
[TBL] [Abstract][Full Text] [Related]
15. [Molecular marker for hemostasis and thrombosis].
Fukutake K; Fujimaki M
Nihon Rinsho; 1989 Apr; 47(4):883-90. PubMed ID: 2664266
[No Abstract] [Full Text] [Related]
16. [Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin].
Blanke H; Praetorius G; Leschke M; Seitz R; Egbring R; Strauer BE
Klin Wochenschr; 1987 Aug; 65(16):757-63. PubMed ID: 2958657
[TBL] [Abstract][Full Text] [Related]
17. Measurement of markers of activated coagulation in antithrombin III deficient subjects.
Demers C; Ginsberg JS; Henderson P; Ofosu FA; Weitz JI; Blajchman MA
Thromb Haemost; 1992 May; 67(5):542-4. PubMed ID: 1519214
[TBL] [Abstract][Full Text] [Related]
18. Coagulation and fibrinolysis in patients with chronic renal failure on maintenance hemodialysis.
Deguchi K; Izumi K; Noguchi M; Yuwasaki E; Suzuki H; Mori Y; Deguchi A; Ohkubo I; Tsuda M; Wada H
Nihon Ketsueki Gakkai Zasshi; 1989 Feb; 52(1):140-6. PubMed ID: 2741646
[TBL] [Abstract][Full Text] [Related]
19. Comparison of thrombin-antithrombin complex (TAT) levels and fibrinopeptide A following thrombin incubation of human plasma using hirudin as an inhibitor of TAT formation.
Haaland AK; Skjønsberg OH; Gravem K; Ruyter R; Godal HC
Thromb Res; 1991 Feb; 61(3):253-9. PubMed ID: 2028444
[TBL] [Abstract][Full Text] [Related]
20. Activation of coagulation and fibrinolysis during surgery, analyzed by molecular markers.
Kambayashi J; Sakon M; Yokota M; Shiba E; Kawasaki T; Mori T
Thromb Res; 1990 Oct; 60(2):157-67. PubMed ID: 2149215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
